Roundhill Glp-1 & Weight Loss ETF OZEM
31.24 USD -0.49 (-1.54%)
Nov 12, 2026, 10:26 AM EST
31.34 Day range 31.36
28.34 52-week range 37.15
- YTD
- -8.55%
- 1 year
- -0.86%
News
benzinga.com EXCLUSIVE: Trump 'Amplified' Several Investing Themes – ETF CEO Picks 3 Sectors Benefitting The Most President Donald Trump may be creating investment opportunities in themes and helping put an emphasize thematic ETFs.
benzinga.com Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval Food makers and restaurants adjust menus and products as GLP-1 drugs drive demand for high-protein foods and smaller portions across the U.S.
benzinga.com Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
benzinga.com Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
benzinga.com EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
benzinga.com EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."
benzinga.com EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market.